As of today (2024-04-29), the Trailing Annual Dividend Yield of Cara Therapeutics is 0.00%.
The historical rank and industry rank for Cara Therapeutics's Dividend Yield % or its related term are showing as below:
CARA's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Cara Therapeutics Dividend Yield % Historical Data
The historical data trend for Cara Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cara Therapeutics's Dividend Yield %
For the Biotechnology subindustry, Cara Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cara Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's Dividend Yield % falls into.
Cara Therapeutics Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Cara Therapeutics (NAS:CARA) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Cara Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cara Therapeutics (Cara Therapeutics) Business Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CARA has been successfully added to your 